| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.4 | 0.4 |
| Gross profit | 0.1 | 0.1 |
| Net income | -1.4 | -0.8 |
| EPS (diluted, $ a share) | $-0.12 | $-0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -9.0% |
|---|---|
| Gross margin | 25.5% |
| Operating margin | -365.6% |
10-Q filed with the SEC, NASDAQ: AIDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
20/20 Biolabs, Inc.: key numbers
- Share price
- $0.1874Close, Nov 17
- Market cap
- $2.62M
- Shares outstanding
- 13.99MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Testing LaboratoriesSIC 8734
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from 20/20 Biolabs, Inc.
All →20/20 Biolabs Financial Results
20/20 Biolabs reported its Q3 2026 financial results, highlighted by a 4.1% increase in OneTest revenue to $1.36 million for the first nine months of the year and a gross margin expansion to 32.8%. The company ended the quarter with $3.63 million in cash and no debt, while securing a new two-year firefighter cancer screening contract with the state of Vermont expected to contribute to revenue in Q4.
- Term
- Q3 2026
“OneTest™ revenue grew 4.1% through the first nine months of the year, with gross profit increasing 15.6%. While third quarter revenue was below the prior year, much of this reflected the timing of our state-funded firefighter cancer screening programs. Maryland completed a significant portion of its testing in the second quarter, while the start of Vermont’s program shifted into the fourth quarter. Vermont has now executed its two-year contract, and we expect testing to begin contributing to revenue before year-end.”
Jonathan Cohen, President and Chief Executive Officer
“We ended the third quarter with $3.63 million in cash and no outstanding borrowings, compared to $1.03 million in cash at year-end 2025. Our net loss narrowed to $1.38 million from $1.51 million in the second quarter, while operating expenses declined 4.0% sequentially.”
Alan Bergman, Chief Financial Officer
20/20 Biolabs Shareholder Meeting
20/20 Biolabs, Inc. reported the results of its adjourned annual meeting of stockholders held on September 16, 2026. Stockholders approved a charter amendment to increase the number of authorized shares of common stock from 50 million to 500 million shares.